The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Radiotherapy to augment pembrolizumab responses and outcomes in metastatic non-small cell lung cancer: Pooled analysis of two randomized trials.
 
James William Welsh
Employment - MD Anderson Cancer Center; MD Anderson Cancer Center
Leadership - MolecularMatch; MolecularMatch
Stock and Other Ownership Interests - Alpine Immune Sciences; Checkmate Pharmaceuticals; Mavupharma; MolecularMatch; Nanobiotix; Nanorobotix; Oncorena; Reflexion Medical; Reflexion Medical
Honoraria - Aileron Therapeutics; American Association of Physicists in Medicine; Nanobiotix; Reflexion Medical; Shandong Cancer Hospital; The Korean Society for Radiation Oncology
Consulting or Advisory Role - Alpine Immune Sciences; AstraZeneca; Checkmate Pharmaceuticals; Legion Healthcare Partners; Mavu Pharmaceutical; MolecularMatch; Oncorena; Reflexion Medical
Research Funding - Aileron Therapeutics; Bristol-Myers Squibb; Checkmate Pharmaceuticals; Checkmate Pharmaceuticals; Mavu Pharmaceutical; Merck; Nanobiotix
Patents, Royalties, Other Intellectual Property - MolecularMatch
Travel, Accommodations, Expenses - AACR; Aileron Therapeutics; American Society for Radiation Oncology; Gustave Roussy Cancer Center; IASLC; MedAustron; Nanobiotix; Radiation Research Society; Reflexion Medical; Shandong Cancer Hospital; The Korean Society for Radiation Oncology; The Korean Society for Radiation Oncology; The Korean Society for Radiation Oncology; Turkish Society of Lung Cancer
 
Dawei Chen
No Relationships to Disclose
 
Paul Baas
Honoraria - AstraZeneca; Bristol-Myers Squibb
Consulting or Advisory Role - Aduro Biotech (Inst); Aldeyra Therapeutics (Inst); Aldeyra Therapeutics (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst)
Research Funding - Bristol-Myers Squibb (Inst); Merck Sharp & Dohme (Inst)
Travel, Accommodations, Expenses - Merck Sharp & Dohme
Other Relationship - Bristol-Myers Squibb
 
Joe Y. Chang
Stock and Other Ownership Interests - Global Advisory Board Medi-Globe
Honoraria - Varian Medical Systems
Consulting or Advisory Role - AstraZeneca
Research Funding - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Varian Medical Systems
 
Vivek Verma
No Relationships to Disclose
 
Nathan Comeaux
No Relationships to Disclose
 
Ferdinandos Skoulidis
Honoraria - Bristol-Myers Squibb
 
Steven H. Lin
Honoraria - AstraZeneca/MedImmune
Speakers' Bureau - Varian Medical Systems
Research Funding - Genentech/Roche; Hitachi Chemical; New River Labs; STCube Pharmaceuticals Inc.
 
John Heymach
Stock and Other Ownership Interests - Bio-Tree; Cardinal Spine
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; EMD Serono; Genentech/Roche; GlaxoSmithKline; Guardant Health; Hengrui Pharmaceutical; Lilly; Sanofi/Aventis; Spectrum Pharmaceuticals; Syntha Pharmaceutical; Takeda
Research Funding - AstraZeneca (Inst); Bayer; GlaxoSmithKline; Spectrum Pharmaceuticals
Patents, Royalties, Other Intellectual Property - Licensing agreement between Spectrum and MD Anderson (including myself) regarding intellectual property for treatment of EGFR and HER2 exon 20 mutations
 
W. Theelen
No Relationships to Disclose